By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Proteome Sciences and the Buck Institute for Research on Aging announced today a collaboration to develop mass spectrometry-based tests aimed at improving response to breast cancer therapies.

Under the terms of the deal, Proteome Sciences will support the development of mass spec assays that measure changes in estrogen receptor alpha, a biomarker associated with response to anti-estrogen therapies for breast cancer.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.